Dose-dependent reductions in A1C and body weight at higher doses in people with type 2 diabetes have been demonstrated in the phase 2 evaluation of oral semaglutide, suggesting that oral semaglutide at higher doses may provide a more individualized treatment option in people with type 2 diabetes who need additional glycemic control and/or additional weight reduction, explained Sue Pedersen, MD, FRCPC, Specialist in Endocrinology and Metabolism at C-ENDO Diabetes & Endocrinology Clinic, Calgary, Canada
Oct 14 : Bristol Myers Squibb can add another adjuvant indication to Opdivos label after the FDA approved the immunotherapy blockbuster to treat patients 12 and older with completely resected stage IIB or IIC melanoma
Loh JS, Mak WQ, Tan LKS, Ng CX, Chan HH, Yeow SH, et al
It reduces protein levels in their urine, lowers kidney inflammation, and decreases blood pressure
These reduce per-month costs but increase total upfront investment